CVAC'ün son EPS'si beklentilerle karşılaştırıldığında nasıldı?
CureVac NV CVAC'ün son çeyrekteki geliri nasıl performans gösterdi?
CureVac NV'in gelir tahmini nedir?
CureVac NV'in kazanç kalite puanı nedir?
CureVac NV kazançlarını ne zaman rapor eder?
CureVac NV'in beklenen kazançları nelerdir?
CureVac NV kazanç beklentilerini aştı mı?
Önemli İstatistikler
Önceki Kapanış
$4.66
Açılış fiyatı
$4.57
Günün Aralığı
$4.57 - $4.66
52 haftalık aralık
$2.48 - $5.72
İşlem hacmi
728.7K
Ort.Hacim
910.3K
EPS (TTM)
0.57
Dividend yield
--
Piyasa Değeri
$1.0B
CVAC nedir?
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 825 full-time employees. The company went IPO on 2020-08-14. The firm develops transformative medicines based on messenger ribonucleic acid, or mRNA. The firm's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The firm's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).